Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353653 | 0.83 | RPS6KB1 (0.46) | CD38RPS6KB1KDM4EALDH1A1GAA | |
| SCHEMBL352441 | 0.76 | RPS6KB1 (0.46) | CD38RPS6KB1KDM4EALDH1A1PARP1 | |
| SCHEMBL634715 | 0.73 | KMT2A (0.46) | KDM4EALDH1A1GAAPARP1KMT2A | |
| SCHEMBL353377 | 0.70 | SIRT2 (0.47) | CD38RPS6KB1KDM4EALDH1A1GAA | |
| SCHEMBL11607263 | 0.70 | CYP1A2 (0.54) | CD38CYP3A4KCNH2RPS6KB1KDM4E | |
| SCHEMBL6135290 | 0.70 | ATM (0.61) | KDM4EALDH1A1GAAPARP1KMT2A | |
| SCHEMBL241943 | 0.69 | RPS6KB1 (0.41) | RPS6KB1KDM4EALDH1A1GAAPARP1 | |
| SCHEMBL355056 | 0.69 | HSD17B1 (0.43) | CD38CYP3A4KCNH2KDM4EALDH1A1 | |
| SCHEMBL634722 | 0.68 | ATM (0.55) | KDM4EALDH1A1GAAPARP1KMT2A | |
| SCHEMBL8580446 | 0.66 | KDM4E (0.50) | KDM4EALDH1A1GAAPARP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | CD38 3165/4885CYP3A4 1848/4885KCNH2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.